Cargando…

Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma

Galectin-4 is a multifunctional lectin found at both intracellular and extracellular sites. It could serve as a tumor suppressor intracellularly and promote tumor metastases extracellularly during colorectal cancer development. However, galectin-4 expression and its prognostic value for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Zhixiong, Zeng, Yongyi, Xu, Bo, Gao, Yunzhen, Wang, Sen, Zeng, Jinhua, Chen, Lihong, Huang, Aimin, Liu, Xiaolong, Liu, Jingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462376/ https://www.ncbi.nlm.nih.gov/pubmed/25230111 http://dx.doi.org/10.1111/cas.12536

Ejemplares similares

α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC
por: Xu, Bo, et al.
Publicado: (2014)

Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection
por: Huang, Xinhui, et al.
Publicado: (2014)

Dataset for the quantitative proteomics analysis of the primary hepatocellular carcinoma with single and multiple lesions
por: Xing, Xiaohua, et al.
Publicado: (2015)

Prognostic Significance of Platelet-to-Lymphocyte Ratio (PLR) in Extrahepatic Metastasis of Hepatocellular Carcinoma After Curative Resection
por: Chen, Yifan, et al.
Publicado: (2021)

Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection
por: Huang, Yao, et al.
Publicado: (2021)

Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns
por: Li, Zhenli, et al.
Publicado: (2021)

The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
por: Wang, Lei, et al.
Publicado: (2017)

The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
por: Liu, Hongzhi, et al.
Publicado: (2019)

EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis
por: Gu, Fangming, et al.
Publicado: (2019)

Circular RNA profiling identifies circADAMTS13 as a miR‐484 sponge which suppresses cell proliferation in hepatocellular carcinoma
por: Qiu, Liman, et al.
Publicado: (2019)

Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study
por: Zeng, Jianxing, et al.
Publicado: (2020)

Prognostic significance of three‐tiered pathological classification for microvascular invasion in patients with combined hepatocellular‐cholangiocarcinoma following hepatic resection
por: Wu, Yijun, et al.
Publicado: (2022)

Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review
por: Lin, Nanping, et al.
Publicado: (2020)

CTHRC1 May Serve As A Prognostic Biomarker For Hepatocellular Carcinoma
por: Zhou, Huifang, et al.
Publicado: (2019)

Aldolase B inhibits metastasis through Ten–Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma
por: Tao, Qi-fei, et al.
Publicado: (2015)

Role of exosomes in hepatocellular carcinoma cell mobility alteration
por: Wang, Sen, et al.
Publicado: (2017)

Novel inflammation-based prognostic nomograms for individualized prediction in hepatocellular carcinoma after radical resection
por: Zeng, Jianxing, et al.
Publicado: (2020)

NEK2 serves as a prognostic biomarker for hepatocellular carcinoma
por: Li, Gang, et al.
Publicado: (2017)

Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study
por: Wu, Yijun, et al.
Publicado: (2022)

Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
por: Cai, Zhixiong, et al.
Publicado: (2021)

Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma
por: Lin, Kongying, et al.
Publicado: (2021)

Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma
por: Huang, Yao, et al.
Publicado: (2020)

Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
por: Lin, Kongying, et al.
Publicado: (2020)

MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence
por: Liu, Mingyu, et al.
Publicado: (2018)

Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization
por: Ke, Qiao, et al.
Publicado: (2021)

PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma
por: Jiang, Xiaocong, et al.
Publicado: (2021)

SAMD13 serves as a useful prognostic biomarker for hepatocellular carcinoma
por: Yoo, Wonbeak, et al.
Publicado: (2023)

Prognostic Value of MicroRNA-497 in Various Cancers: A Systematic Review and Meta-Analysis
por: Liu, Zhiqiang, et al.
Publicado: (2019)

Gadolinium-doped hollow CeO(2)-ZrO(2) nanoplatform as multifunctional MRI/CT dual-modal imaging agent and drug delivery vehicle
por: Wei, Zuwu, et al.
Publicado: (2018)

PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition
por: Leng, Shusheng, et al.
Publicado: (2017)

CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma
por: Tang, Kaihua, et al.
Publicado: (2023)

DAPK1 as an independent prognostic marker in liver cancer
por: Li, Ling, et al.
Publicado: (2017)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2017)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2022)

Galectins can serve as biomarkers in COVID-19: A comprehensive systematic review and meta-analysis
por: Behnoush, Amir Hossein, et al.
Publicado: (2023)

Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients
por: Zhu, Weiwei, et al.
Publicado: (2018)

MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53
por: Wang, Yingchao, et al.
Publicado: (2019)

FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma
por: Zhen, Jing, et al.
Publicado: (2023)

Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma
por: Song, Mengjia, et al.
Publicado: (2020)

Galectin-3 as a prognostic biomarker for diabetic nephropathy
por: Hodeib, Hossam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lmvejqs0ck3kmnl3qg3vr7msub